Soluble ST2 in end ‐stage heart failure, before and after support with a left ventricular assist device

ConclusionLevels of sST2 are elevated in end‐stage HF patients with variability that suggests multiple inputs to a pro‐inflammatory and pro‐fibrotic pathway. Cardiogenic shock and increased CRP levels are associated with higher sST2 levels. LVAD support results in a significant drop in sST2 levels with normalization within 3 months post implantation. This suggests that LVAD support leads to lessening of fibrosis and inflammation, which might eventually be used to target medical policy: explantation of the LVAD versus permanent use or cardiac transplantation.This article is protected by copyright. All rights reserved.

Source: European Journal of Clinical Investigation - January 1, 2018 Category: General Medicine Authors: C.C.S. Tseng, M.M.H. Huibers, L. H. Gaykema, E. Siera ‐de Koning, F.Z. Ramjankhan, A.S. Maisel, N. de Jonge Tags: Original Paper Source Type: research